Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats.
Injection of the endogenous methyl donor, S-adenosyl methionine (SAM), into rat brain induces Parkinson's disease (PD)-like symptoms possibly by stimulating deleterious protein methylation. Gel-filtration chromatography of rat brain extracts treated with [3H-methyl]-SAM revealed the presence of radioactive peaks with apparent molecular weights of about 5 kDa. Treatment with guanidine HCl altered the elution volumes of the labeled peaks. Lyophilized peak fractions released volatile 3H-methanol on incubation with NaOH, indicating the presence of carboxyl methyl esters. Because prenylated proteins are avid methyl acceptors at the terminal carboxylic acid groups, 1 micromol S-farnesylcysteine (FC) analogs blocked the SAM-induced tremors in the experimental rats. FC analogs did not only reverse the associated rigidity, abnormal posture, and hypokinesia, but stimulated hyperactivity in the animals. This amphetamine-like effect was monitored for 20 min in an animal activity monitor and movement times between 400 +/- 100 and 560 +/- 125 s covering distances between 78 +/- 29 to 125 +/- 35 m were recorded for rats treated with FC analogs with or without SAM. Control animals moved only for 60 +/- 13 s covering about 6 +/- 1 m, indicating a 7-9-fold and 13-21-fold increase in duration of movement and distance covered, respectively. N-Acetyl-S-farnesylcysteine (AFC) potentiated amphetamine-induced ipsiversive rotation of 6-hydroxydopamine-lesioned rats from 390 +/- 130 to 830 +/- 110, with AFC alone having no significant effect on net rotation compared to controls. These data indicate that intracerebroventricular injection of SAM may induce PD symptoms by interfering with the methylation/demethylation homeostasis of prenylated proteins that function in the dopaminergic and other signaling pathways, and that the FC analogs may counteract the SAM effects by acting synergistically on events subsequent to neurotransmitter release.
Lamango
N S
NS
College of Pharmacy, Florida A&M University, Tallahassee, FL 32307, USA.
Charlton
C G
CG
D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D002850:Chromatography, Gel; D003545:Cysteine / Q000031:analogs & derivatives* / Q000494:pharmacology; D005612:Freeze Drying; D008297:Male; D008745:Methylation; D009043:Motor Activity / Q000187:drug effects; D009419:Nerve Tissue Proteins / Q000032:analysis / Q000378:metabolism; D016627:Oxidopamine; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012436:S-Adenosylmethionine / Q000037:antagonists & inhibitors* / Q000633:toxicity; D013239:Stereotyped Behavior / Q000187:drug effects; D013563:Sympathectomy, Chemical; D014202:Tremor / Q000139:chemically induced / Q000517:prevention & control
D000697:Central Nervous System Stimulants; D009419:Nerve Tissue Proteins; C057785:S-farnesylcysteine; D012436:S-Adenosylmethionine; D016627:Oxidopamine; D000661:Amphetamine; D003545:Cysteine